Abciximab: A new antiaggregant used in angioplasty

Annals of Pharmacotherapy

Volumn 30, Issue 3, 1996, Pages 251-257

  Genetta, Tina B ^a,b   Mauro, Vincent F ^a,c  

^a UNIVERSITY OF TOLEDO   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

ATHERECTOMY; BLEEDING; BLEEDING TIME; BLOOD CLOTTING TIME; CORONARY ARTERY OBSTRUCTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FIBRINOLYTIC THERAPY; FOOD AND DRUG ADMINISTRATION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM;

EID: 0029984660     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000309     Document Type: Review

References (28)

1. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, et al Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 1991;614:193-213.
2. Bennett JS. Mechanisms of platelet adhesion and aggregation: an update. Hosp Pract 1992;24:124-40.
3. Handin RI, Loscalzo J Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In: Braunwald E, ed. Heart disease. A textbook of cardiovascular medicine. 4th ed. Philadelphia: WB Saunders. 1992:1767-89.
4. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-8.
5. Product information. ReoPro (abciximab). Malvern, PA: Centocor, February 1995.
6. Azrin MA. The use of antibodies in clinical cardiology. Am Heart J 1992;124:753-68.
7. Jordan RE, Knight DM, Wagner C, McAleer MF, McDonough M, Mattis JA, et al. A dramatic reduction of the immunogenicity of the anti-GPIIb/IIIa monoclonal antibody, 7E3 Fab, by humanization of the murine constant domains (abstract). Circulation 1992;86(suppl I):411.
8. Wagner CL, Knight D, McAleer MF, Lance E, Mattis J, Coller B, et al. Immunological comparison of murine and chimeric 7E3 Fab fragments in human clinical trials (abstract). J Immunol 1993;150.158A.
9. Turner NA, Moake JL, Kumat S, McIntire LV. Comparative effects on platelet aggregation in real-time under flowing conditions of in vivo aspirin, heparin and monoclonal antibody 7E3 against glycoprotein IIb-IIIa (abstract). Blood 1993;82(suppl 1):282a.
10. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990;86:651-9.
11. Christopoulos C, Mackie I, Lahiri A, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis 1993;4:729-37.
12. Simoons ML, de Boer MJ, van den Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
13. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994:90:1757-64.
14. Bhattacharya S, Weisman HF, Morris KG, Miller MJ, Jordan RE, Senior R, et al. Chimerization of monoclonal antibody 7E3 preserves the GPIIb/IIIa receptor blockade and platelet functional inhibition of murine 7E3 (abstract). Clin Res 1991;39:196A.
15. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KM, Weisman HF, et al. Effect of platelet glycoprotein IIb/IIIa intergrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol 1995;75:559-62.
16. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal anti-platelet GPIIb/IIIa antibody in a dog model. Circulation 1988;77:670-7.
17. Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988;81:1284-91.
18. Ellis SG, Tcheng JE, Navetta FI, Muller DWM, Weisman HF, Smith C, et al. Safety and antiplatelet effect of marine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coronary Artery Dis 1993;4:167-75.
19. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61
20. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
21. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, et al. Profound inhibition of platelet aggregation with monoclonal antibody to 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993;22:381-9.
22. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994;330:981-93.
23. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD, et al. ACC/AHA task force report. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 1988;12:529-45.
24. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in myocardial infarction (TIMI) trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
25. Boehrer JD, Kereiakes D, Navetta FT, Califf RM, Topol EJ. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol 1994;74:1166-70.
26. Aguirre F, Ferguson JJ, Califf RM. Clinical predictors of bleeding complications in high risk angioplasty patients: results from the EPIC study group (abstract). Circulation 1993:88(suppl I):I-252.
27. Christopoulos C. Platelet surface IgG in patients receiving infusions of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa. Clin Exp Immunol 1994;98:6-11.
28. Brezina K, Murphy M, Stonner T. Care of the patient receiving ReoPro following angioplasty J Invasive Cardiol 1994:6(suppl A).38A-42A.